– Oversubscribed Series B round led by TPG includes prominent group of new and existing investors, bringing total raised to-date to over $110 million– Funding supports rapid clinical development of targeted ADC therapeutics in difficult-to-treat cancers – Chris LeMasters joins as Independent Board Member, bringing 2.
Lumira Ventures Portfolio Company enGene (Nasdaq:ENGN) Debuts as Publicly Traded Genetic Medicines Company pittsburghstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pittsburghstar.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ - enGene Holdings Inc. ("enGene" or the "Company,") (NASDAQ: ENGN) today announced the completion of the previously announced business combination.